← Back to Search
Cancer Immunotherapy Comes Of Age
I. Mellman, G. Coukos, G. Dranoff
Published 2011 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Activating the immune system for therapeutic benefit in cancer has long been a goal in immunology and oncology. After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clinical trials. Most notable has been the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a significant increase in survival for patients with metastatic melanoma, for which conventional therapies have failed. In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.
This paper references
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
H. Nishimura (1999)
Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects.
L. Zitvogel (2009)
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
N. Hunder (2008)
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab
Dirk Nagorsen (2009)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
J. Hamanishi (2007)
Ido expression by dendritic cells: tolerance and tryptophan catabolism
A. Mellor (2004)
Epitope landscape in breast and colorectal cancer.
N. Segal (2008)
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
E. Small (2000)
The role of CD4+ T cell responses in antitumor immunity.
D. Pardoll (1998)
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
M. Dudley (2008)
A recent and clinically impressive attempt at adoptive T-cell therapy using genetically altered, patient-derived T cells
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
J. Kirkwood (2001)
[Immunology of melanoma].
R. Vanwijck (1974)
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
M. Dudley (2002)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
T. Eberlein (2012)
Does the immune system see tumors as foreign or self?
D. Pardoll (2003)
OX40 ligand shuts down IL-10-producing regulatory T cells
T. Ito (2006)
A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma
M. Dudley (2002)
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
J. Yang (2007)
CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers
K. Kono (2005)
Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
B. Li (2009)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
H. Nishimura (2001)
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.
X. Zhong (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi (2010)
Bacillus Calmette–Guérin treatment of non‐muscle invasive bladder cancer
R. Sylvester (2011)
Immune therapy for cancer.
M. Dougan (2009)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
T. Curiel (2004)
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
A. Facciabene (2011)
Feedback control of regulatory T cell homeostasis by dendritic cells in vivo
G. Darrasse-Jèze (2009)
Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation
A. Loren (2008)
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.
Siao-Yi Wang (2008)
Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial
N. Leffers (2009)
Whole-cell vaccines: A failure or a success waiting to happen?
J. Copier (2010)
Toll - like receptors and their crosstalk with other innate receptors in infection and
T Kawai (2011)
Inhibitory B7-family molecules in the tumour microenvironment
W. Zou (2008)
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.
H. Gerber (2009)
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX1
Andrew W. Pawluczkowycz (2009)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
Prognostic significance of autoimmunity during treatment of melanoma with interferon
M. Krauze (2011)
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
G. Kenter (2009)
CTLA-4 Control over Foxp3+ Regulatory T Cell Function
K. Wing (2008)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
J. Galon (2006)
Human T cell responses against melanoma.
T. Boon (2006)
mechanisms of action and resistance
R. Nahta (2006)
Cancer immunotherapy: moving beyond current vaccines
S. Rosenberg (2004)
Rituximab: mechanism of action.
G. Weiner (2010)
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
T. Eberlein (2012)
Programmedcell death 1 ligand 1 and tumor-infiltratingCD81 T lymphocytes are prognostic factors of human ovarian cancer
J Hamanishi (2007)
L.,Kalos,M., Bagg, A.&June,C.H.Chimeric antigenreceptormodified T cells in chronic lymphoid leukemia
D. L. Porter (2011)
Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC)
J. Vansteenkiste (2007)
A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism
E. A. Manning (2007)
Translational Research Working Group developmental pathway for immune responsemodifiers.Clin.CancerRes.14,5692–5699
Novel Gamma-Chain Cytokines as Candidate Immune Modulators in Immune Therapies for Cancer
Natasha M. Fewkes (2010)
Cell biology of antigen processing in vitro and in vivo.
E. S. Trombetta (2005)
Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells
I. Marigo (2008)
a failure or a success waiting to happen? Curr
J. Copier (2010)
rapamycin augments pathogen-specific but not graft-reactive CD81 T cell responses
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
P. Kantoff (2010)
Antigens for cancer immunotherapy.
M. Neller (2008)
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
L. Johnson (2009)
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.
A. Hurwitz (1998)
IAP inhibitors enhance co-stimulation to promote tumor immunity
M. Dougan (2010)
Myeloid-derived suppressor cells as regulators of the immune system
D. Gabrilovich (2009)
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.
R. Shrimali (2010)
Tumor-infiltrating lymphocytes: apparently good for melanoma patients
A Cipponi (2011)
Discontinued drugs in 2005: oncology drugs
L. Kelland (2006)
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.
J. Bowles (2006)
Calreticulin exposure dictates the immunogenicity of cancer cell death
M. Obeid (2007)
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
A. Cohen (2010)
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
L. Wang (2009)
Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)1
C. Workman (2005)
proved survival with ipilimumab in patients with metastatic melanoma
FS Hodi (2010)
Epitope landscape inbreast andcolorectal cancer
N. H. Segal (2008)
tolerance and tryptophan catabolism
A. L. Mellor (2004)
Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells
J. Greiner (2008)
Human tumor antigens recognized by T cells.
P. Robbins (1996)
PD‐1/PD‐L1 pathway and T‐cell exhaustion in chronic hepatitis virus infection
T. Watanabe (2010)
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.
L. Emens (2009)
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
F. Ghiringhelli (2006)
A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies.
D. McDermott (2011)
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
L. Apetoh (2007)
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
T. Okazaki (2011)
HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
S. Kooi (1996)
Improved Endpoints for Cancer Immunotherapy Trials
A. Hoos (2010)
Designing vaccines based on biology of human dendritic cell subsets.
K. Palucka (2010)
Towards patient‐specific tumor antigen selection for vaccination
Hans-Georg Rammensee (2002)
Cutting Edge: Rapamycin Augments Pathogen-Specific but Not Graft-Reactive CD8+ T Cell Responses
I. Ferrer (2010)
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
D. Porter (2011)
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
A. J. Muller (2006)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
G. Suntharalingam (2006)
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
M. Pule (2008)
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
S. Topalian (1988)
Human mesenchymal stem cells modulate allogeneic immune cell responses.
S. Aggarwal (2005)
Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.
S. Mackinnon (1995)
safety, clinical activity, pharmacodynamics, and immunologic correlates
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
G. Sonpavde (2011)
Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events.
H. Buening (2010)
Allogeneic transplantation for lymphoma.
R. Chakraverty (2011)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
F. Ghiringhelli (2009)
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Gail D Lewis Phillips (2008)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
Time-dependent cytotoxic drugs selectively cooperate with IL18 for cancer
I Alagkiozidis (2011)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
A. Parsa (2007)
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
J. Machiels (2001)
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E. Tivol (1995)
IDO and tolerance to tumors.
D. Munn (2004)
Effects of Vascular Endothelial Growth Factor on the Lymphocyte-Endothelium Interactions: Identification of Caveolin-1 and Nitric Oxide as Control Points of Endothelial Cell Anergy1
C. Bouzin (2007)
TargetingHER 2positivebreast cancerwith trastuzumabDM 1 , an antibodycytotoxic drug conjugate
G. D. Lewis Phillips (2008)
Translational Research Working Group Developmental Pathway for Immune Response Modifiers
M. Cheever (2008)
apparently good for melanoma patients
A. Cipponi (2011)
Anti - PD - 1 and - B 7 – H 1 / PD - L 1 monoclonal antibodies
Signaling through OX40 enhances antitumor immunity.
S. Jensen (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
M. Curran (2010)
Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy
C. Taylor (2007)
Tolerogenic dendritic cells.
R. Steinman (2003)
Role of LAG-3 in regulatory T cells.
C. Huang (2004)
T. Greten (2001)
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
A. Freedman (2009)
Dendritic cells in cancer immunotherapy
G. Schuler (2010)
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
P. Kantoff (2010)
Opportunities and challenges in the development of experimental drug combinations for cancer.
R. Humphrey (2011)
The promise of 4‐1BB (CD137)‐mediated immunomodulation and the immunotherapy of cancer
D. H. Lynch (2008)
al.A2A adenosine receptorprotects tumors from antitumor T cells
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.
M. Disis (1997)
A listing of human tumor antigens recognized by T cells: March 2004 update
L. Novellino (2004)
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
Q. Gao (2009)
Application of IL-2 and other cytokines in renal cancer
D. McDermott (2004)
The authors summarize the current state of the art use of autologous dendritic cell vaccines
Immune regulation of cancer.
M. Disis (2010)
Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
D. Porter (1994)
PD-1 and its ligands in tolerance and immunity.
M. Keir (2008)
Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation.
Aimin Jiang (2007)
The Induction of Tolerance by Dendritic Cells That Have Captured Apoptotic Cells
R. Steinman (2000)
Dendritic Cells Specialized and Regulated Antigen Processing Machines
I. Mellman (2001)
A Commotion in the Blood: Life, Death, and the Immune System
S. Hall (1997)
Regulatory T Cells: Overcoming Suppression of T-Cell Immunity
T. Golovina (2010)
Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells.
J. Shin (2009)
immune-related response criteria
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
J. Brahmer (2010)
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?
A. Cipponi (2011)
Role of KIRs and KIR ligands in hematopoietic transplantation.
A. Velardi (2008)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
R. Clynes (2000)
A listing of human tumor antigens recognized by T cells
N. Renkvist (2001)
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
Y. Zhao (2010)
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
R. Schreiber (2011)
Overall survival and PD‐L1 expression in metastasized malignant melanoma
J. Gadiot (2011)
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy
Ioannis Alagkiozidis (2010)
moving beyond current vaccines
S. A. Rosenberg (2004)
Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients
A. M. Thomas (2004)
GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
T. Robak (2009)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
L. Zhang (2003)
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.
C. A. Chambers (2001)
identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy
C. Bouzin (2007)
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.
G. Gross (1989)
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
M. Topp (2011)
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
R. Buckanovich (2008)
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. S. Hodi (2008)
Roleof LAG-3 in regulatoryT cells
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
S. Treon (2005)
Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.
M. Sznol (2010)
Differential subcellular localization of the regulatory T‐cell protein LAG‐3 and the coreceptor CD4
Seng-Ryong Woo (2010)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
M. Kalos (2011)
Chimeric antigen receptormodified T cells in chronic lymphoid leukemia
D L Porter (2011)
In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.
D. Schwartzentruber (1994)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
J. Kochenderfer (2010)
Adoptive Cell Therapy: Genetic Modification to Redirect Effector Cell Specificity
R. Morgan (2010)
Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance.
Stephanie O. Harbers (2007)
rapamycin augments pathogen-specific but not graft-reactive CD81 T cell responses
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
P. Robbins (2011)
Principles of adoptive T cell cancer therapy.
C. June (2007)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
Guidelines for the evaluationof immune therapyactivity insolid tumors : immunerelated response criteria
J. D. Wolchok (2009)
March 2004 update
L. Novellino (2005)
Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood
S Aggarwal (2005)
Papillomaviruses in the causation of human cancers — a brief historical account
H. Hausen (2009)
Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
M. Besser (2010)
Clearance of hepatitis C in chimpanzees is associated with intrahepatic T‐cell perforin expression during the late acute phase
H. Watanabe (2010)
The B7–CD28 superfamily
A. Sharpe (2002)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
W. Weng (2003)
Trastuzumab--mechanism of action and use in clinical practice.
C. Hudis (2007)
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
S. Rosenberg (1994)
Phase I study of singleagent antiprogrammeddeath1 ( MDX1106 ) in refractory solid tumors : safety , clinical activity , pharmacodynamics , and immunologic correlates
J. R. Brahmer (2010)
A 2 Aadenosine receptorprotects tumors fromantitumorT cells
A. Ohta (2006)
A2A adenosine receptor protects tumors from antitumor T cells
A. Ohta (2006)
Clinical development of the anti-CTLA-4 antibody tremelimumab.
A. Ribas (2010)
Herceptin: mechanisms of action and resistance.
R. Nahta (2006)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
S. Gende (2011)
overcoming suppression of T-cell immunity
T. N. Golovina (2010)
Anti-PD-1 and -B7–H1/PD-L1 monoclonal antibodies, in Gajewski TF, Hodi FS (eds): Targeted Therapeutics in Melanoma
EF Lipson (2011)
The authors summarize the argument for using a different set of criteria to evaluate the efficacy of immunotherapies given the mechanistic differences from conventional anticancer drugs
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity.
T. Kawai (2011)
CARs on track in the clinic.
D. Kohn (2011)
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
S. Dall'ozzo (2004)
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
A. Younes (2010)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.
N. Senzer (2009)
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
S. Rosenberg (2008)
This paper is referenced by
Cancer immunotherapy with a gene modified serotype 3 oncolytic virus
Otto Hemminki (2015)
Immunotherapy with immunomodulatory antibody for hepatocellular carcinoma
Liang Huang (2016)
Chapter 9 – New Targeted Therapies for Brain Metastases from Breast and Lung Cancer and Melanoma
Emmanouil Fokas (2015)
Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes
L. Hanker (2012)
Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers
D. Y. B. Seow (2020)
Vaccines Developed for Cancer Immunotherapy
Aizong Shen (2018)
Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer
Kosuke Kawaguchi (2016)
Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells
F. Antonangeli (2016)
Preclinical vaccines against mammary carcinoma
Pier-Luigi Lollini (2013)
TIME for a successful cancer vaccine in NSCLC?
C. Butts (2016)
Antitumor Effect of Nivolumab on Subsequent Chemotherapy for Platinum-Resistant Ovarian Cancer.
Y. Inayama (2018)
When transgenes shape immunity: cancer immune‐gene therapy
C. Bonini (2012)
Genetic Engineering of Hematopoiesis for Targeted IFN-α Delivery Inhibits Breast Cancer Progression
Giulia Escobar (2014)
A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy.
E. Yuba (2013)
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
M. Hölzel (2013)
Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
A. Tarhini (2013)
Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries.
Ping-Chih Ho (2017)
Combinatorial immunotherapy and nanoparticle mediated hyperthermia.
Austin J. Moy (2017)
A peptide-modified solid lipid nanoparticle formulation of paclitaxel modulates immunity and outperforms dacarbazine in a murine melanoma model.
Indranil Banerjee (2019)
Adverse effects and radiological manifestations of new immunotherapy agents.
Y. Tang (2018)
Immunothérapie : les checkpoints
C. Caux (2016)
Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era.
Everett J. Moding (2016)
NK Cells in Antitumor Immunity
A. Cerwenka (2016)
B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy
J. Ma (2016)
PI3K/Akt Cooperates with Oncogenic Notch by Inducing Nitric Oxide-Dependent Inflammation.
S. Villegas (2018)
Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity.
Myunggi An (2018)
Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles
A. Rodallec (2018)
Investigative therapy for advanced esophageal cancer using the option for combined immunotherapy and chemotherapy.
Huan Wang (2020)
Ex vivo generation of functional immune cells by mitochondria-targeted photosensitization of cancer cells.
Sean Marrache (2015)
Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions
L. Radvanyi (2015)
Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor
Q. Li (2016)
New use of microsatellite instability analysis in endometrial cancer
Haruko Kunitomi (2017)See more